Introduction
The landscape of South America CDMO news updates has shifted dramatically in the closing months of 2025, signaling a new era for regional pharmaceutical self-sufficiency and high-tech manufacturing. Latin America has evolved from secondary packaging to a key hub for complex API manufacturing and advanced biologics. Brazil and Argentina’s infrastructure investment and regulatory alignment are attracting multinationals and strengthening local CDMOs.
CDMO Capsules: The Pulse of South American Pharma
In our latest edition of CDMO Capsules, we explore the pivotal developments shaping the Contract Development and Manufacturing Organization (CDMO) sector across the southern hemisphere. Latin America’s pharmaceutical industry is emerging as a strategic hub for research, production, and development (Mexico Business News, 2025). The following sections provide an extensive summary of the critical news and market shifts recorded over the past month.
Brazil’s Biomanufacturing Boom and Infrastructure Growth
Brazil leads the region with nearly 49% of Latin America’s pharmaceutical contract manufacturing market in late 2025 (Mordor Intelligence, 2025). A standout development this quarter is the continued impact of sizable green-field investments, such as Novo Nordisk’s (https://www.novonordisk.com.br) $1.09 billion GLP-1 facility expansion in Brazil. The project benefits the company while creating a halo effect that attracts specialized CDMOs for secondary packaging and quality services.
Brazil’s cell therapy segment is expected to grow significantly with the rising adoption of Advanced Therapy Medicinal Products (ATMPs). Brazilian institutions are developing domestic CAR-T production to reduce costs and expand access through public funding initiatives. Organizations like Instituto Butantan (https://butantan.gov.br) and Fiocruz (https://www.fiocruz.br) are playing pivotal roles in these public health initiatives, focusing on the development of CAR-T cell therapies and gene-based vaccines (Towards Healthcare, 2025).
Nearshoring and the Regulatory Evolution in Argentina and Colombia
The “Great Reshoring” is pushing North American drugmakers toward South American partners to reduce risk (Mordor Intelligence, 2025). In Argentina, the recovery of domestic sales and a focus on high-value biosimilars have made local CDMOs attractive. Argentina’s oligonucleotide CDMO market is set to hit $29.2M by 2033, growing at a 14.1% CAGR (Grand View Research, 2025).
In Colombia, the focus has pivoted toward niche advanced therapies. The Colombian cell and gene therapy market is benefiting from growing clinical research partnerships and academic-clinical collaborations (Towards Healthcare, 2025). Meanwhile, regulatory bodies like ANVISA (Brazil) (https://www.gov.br/anvisa) have heightened their 2025 agenda with unannounced GMP audits, compelling plants to maintain “perpetual inspection readiness” (Mordor Intelligence, 2025).
Technological Integration and AI in Manufacturing
A significant trend this month is the integration of AI and predictive analytics into the manufacturing process. CDMOs in the region are leveraging AI-driven technology for the automation of manufacturing lines, quality control, and preventative maintenance (Towards Healthcare, 2025). This digital maturity is helping regional players like Scinai Bioservices (https://www.scinai.com), which reported continued CDMO growth in late 2025, to strengthen their position as trusted partners for emerging biotech companies (PR Newswire, 2025).
Moreover, the adoption of green and sustainable manufacturing is becoming a competitive differentiator. CDMOs are increasingly adopting energy-efficient equipment and zero-waste goals in response to both regulatory and societal pressures (Fortune Business Insights, 2025). This proactive approach is helping South American facilities lower their cost of capital through ESG-linked financing (Mordor Intelligence, 2025).
Strategic Shifts in API Production and Market Dynamics
The South American API market is seeing a surge in demand as regional players seek to reduce dependence on Asian imports. Brazil, in particular, has seen a 7.1% CAGR in its CDMO sector, largely driven by synthetic and biotech API segments (Grand View Research, 2025). This shift is supported by government incentives aimed at bolstering local manufacturing of essential medicines (Market Report Analytics, 2025).
Argentina is also making strides, with its CDMO market projected to reach $3.68 billion by 2033 (Grand View Research, 2025). Strong regulatory frameworks and efficient manufacturing position the country as a vaccine development hub (Grand View Research, 2025). This is complemented by the stabilization of Argentina’s economy, which is opening up new opportunities in the private healthcare sector (LAMA Access, 2025).
The Rise of Oral Solid Dosage and Empty Capsule Innovation
Oral solid dosage forms dominate South America’s pharma contract manufacturing market, generating about 55% of total revenue (Roots Analysis, 2025). Demand for empty capsules is set to rise by 2035, driven by health awareness and dietary supplement use (Market Research Future, 2025).
Manufacturers are increasingly focusing on vegetarian and vegan capsules to cater to changing consumer preferences (Market Research Future, 2025). Technological advancements in capsule technologies, such as fast-release and slow-release functionalities, are also enhancing the diversity of offerings in the South American market (Market Research Future, 2025). In Brazil and Argentina, aging populations are boosting demand for easy-to-use dosage forms (Market Research Future, 2025).
Regulatory Harmonization and Modernization Efforts
A key theme in 2025 has been the modernization of regulatory frameworks across South America. ANVISA has introduced measures to optimize approval queues for medicines and clinical trials, utilizing AI through the AnvisAI project to streamline submissions (Pure Global, 2025).This reform will reduce approval times and speed access to innovative healthcare products (Pure Global, 2025).
Similarly, ANMAT in Argentina and INVIMA in Colombia are moving toward harmonization with international standards, such as those set by the ICH (LAMA Access, 2025). The introduction of RDC 964/2025 by ANVISA, which aligns forced degradation studies with international standards, is a clear example of this trend (Lhasa Limited, 2025). These efforts are transforming the region into a more predictable and attractive destination for global pharmaceutical investment (Fifarma, 2025).
Future Outlook: Collaboration and Innovation
The future of the South American CDMO sector will be defined by its ability to innovate and collaborate. The recent agreement between COFEPRIS (Mexico) and ANVISA (Brazil) to strengthen regulatory collaboration and encourage local production sets a positive precedent for the region (Mexico Business News, 2025). As South America strengthens its productive capacity and ensures the resilience of its supply chains, it is poised to become a formidable competitor in the global pharmaceutical value chain (Mexico Business News, 2025).
In conclusion, the South American CDMO market is witnessing a period of unprecedented growth and transformation. Driven by nearshoring, regulatory modernization, and technological integration, the region is successfully positioning itself as a vital player in the global pharmaceutical industry. As we move into 2026, the focus will remain on sustaining this momentum through continued investment and innovation (Mordor Intelligence, 2025)
References and Citations